Published in Cancer Weekly, May 14th, 2002
"High-dose chemotherapy with subsequent autologous stem cell transplantation is believed to be of therapeutic benefit in patients with acute myeloid leukemia (AML), especially when no allogeneic bone marrow donor is available," explained Dr. J. Siehl and colleagues at Benjamin Franklin University Hospital in Berlin, Germany. " One of the main risks is contamination of the stem cell preparations with leukemic blasts, which may account for a higher relapse rate compared...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.